<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453489</url>
  </required_header>
  <id_info>
    <org_study_id>2017-144</org_study_id>
    <secondary_id>NCI-2018-00294</secondary_id>
    <secondary_id>2017-144</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>2017-144</secondary_id>
    <nct_id>NCT03453489</nct_id>
  </id_info>
  <brief_title>AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm</brief_title>
  <official_title>Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies how well telotristat etiprate works in treating participants with&#xD;
      well differentiated neuroendocrine neoplasm that has spread to other places in the body and&#xD;
      monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat&#xD;
      etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. Studying the changes within the tumor cells via AMT-PET may help doctors better&#xD;
      understand how tumors respond to treatment with telotristat etiprate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the effect of telotristat etiprate (telotristat ethyl) treatment in patients&#xD;
      with advanced neuroendocrine tumors (NETs) using carbon C 11 alpha-methyltryptophan&#xD;
      (alpha-[11C]methyl-?L-?tryptophan) (AMT)-?positron emission tomography (PET) as measured by&#xD;
      changes in tumor maximum standardized uptake value (SUVmax).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Show that NETs will have increased AMT uptake on PET, as compared to surrounding non-tumor&#xD;
      tissue at baseline.&#xD;
&#xD;
      II. Use compartmental modeling (in tumors with the left ventricle of the heart in the&#xD;
      field-of-view) to measure change in AMT retention.&#xD;
&#xD;
      III. Measure change in AMT retention as mean standardized uptake value (SUVmean).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat&#xD;
      etiprate treatment. Participants receive telotristat etiprate orally (PO) three times a day&#xD;
      (TID) for 9-14 days.&#xD;
&#xD;
      After completion of study treatment, participants are followed up for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who achieved maximum standardized uptake value (SUVmax) reduction of 20% or more</measure>
    <time_frame>Baseline up to follow up, assessed up to 3 months</time_frame>
    <description>Will be reported with a one-sided, 90% confidence limit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean standardized uptake value (SUVmean)</measure>
    <time_frame>Baseline up to 3 months</time_frame>
    <description>Will be reported as proportions with two-sided exact 95% confidence intervals. Paired t test will be used for pre-and post-treatment SUVs if normality assumption holds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrine tumors visibility</measure>
    <time_frame>At baseline</time_frame>
    <description>Will be reported as proportions with two-sided exact 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal time frame where tumoral AMT uptake peaks</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will use time-activity curves. Will be reported as proportions with two-sided exact 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent difference in carbon C 11 alpha-methyltryptophan (AMT) uptake between the tumor mass and background</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be reported as proportions with two-sided exact 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Carcinoid Syndrome</condition>
  <condition>Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (AMT-PET, telotristat etiprate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbon C 11 Alpha-methyltryptophan</intervention_name>
    <description>Undergo AMT-PET</description>
    <arm_group_label>Treatment (AMT-PET, telotristat etiprate)</arm_group_label>
    <other_name>11C-alpha-methyltryptophan</other_name>
    <other_name>11C-AMT</other_name>
    <other_name>[11C] AMT</other_name>
    <other_name>alpha-[11C]methyl-L-tryptophan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (AMT-PET, telotristat etiprate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo AMT-PET</description>
    <arm_group_label>Treatment (AMT-PET, telotristat etiprate)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telotristat Etiprate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (AMT-PET, telotristat etiprate)</arm_group_label>
    <other_name>LX1032 Hippurate</other_name>
    <other_name>LX1606</other_name>
    <other_name>LX1606 Hippurate</other_name>
    <other_name>TPH Inhibitor LX1606</other_name>
    <other_name>Tryptophan Hydroxylase Inhibitor LX1032</other_name>
    <other_name>Tryptophan Hydroxylase Inhibitor LX1606</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed, well-differentiated metastatic NETs&#xD;
&#xD;
          -  Receiving stable-dose somatostatin analog (long-acting release [LAR], depot) for &gt; 3&#xD;
             months before enrollment.&#xD;
&#xD;
          -  Patients with 5-HIAA levels above or below the upper limit of normal range and those&#xD;
             with unknown values at baseline are allowed to participate.&#xD;
&#xD;
          -  Able to lie within the PET scanner for at least 70 minutes while undergoing scanning.&#xD;
&#xD;
          -  ECOG performance status of 2 or better.&#xD;
&#xD;
          -  Physical exam, CBC and Multiphasic (including electrolytes, BUN, creatinine, total&#xD;
             bilirubin, AST, and ALT) must be done within 28 days of PET imaging and demonstrate&#xD;
             adequate renal and liver function. Creatinine ≤ 2.5, total bilirubin ≤ 1.5 x upper&#xD;
             limit of normal (ULN). AST and ALT ≤ 2.5 ULN.&#xD;
&#xD;
          -  Patient must have a least one lesion greater than 2 cm on standard imaging (CT, MR,&#xD;
             octreotide, or dotatate imaging within 8 weeks of the start of the study) that is&#xD;
             judged amenable to AMT-PET.&#xD;
&#xD;
          -  Women of child bearing potential must not be pregnant or breastfeeding. A negative&#xD;
             urine or blood pregnancy test must be obtained in women with child bearing potential.&#xD;
             Men and women with reproductive potential must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) on study entry and for the&#xD;
             duration of study participation.&#xD;
&#xD;
          -  Eligible and consent signed for imaging with AMT PET under protocol 2011-053.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients experiencing more than 12 watery bowel movements per day associated with&#xD;
             volume contraction, dehydration, or hypotension, or showing evidence of enteric&#xD;
             infection are excluded&#xD;
&#xD;
          -  Patients are excluded if they had undergone tumor-directed therapy within 3 months&#xD;
&#xD;
          -  Patients cannot be on a targeted agent (e.g., sunitinib or everolimus) or receiving&#xD;
             cytotoxic chemotherapy (e.g., capecitabine or temozolomide); they cannnot be on&#xD;
             telotristat ethyl; previous use is acceptable if the patient has been off for over one&#xD;
             month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Shields</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony F. Shields, M.D., PhD</last_name>
      <phone>313-576-8735</phone>
      <email>shieldsa@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Anthony F. Shields, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Csaba Juhasz, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip A. Philip, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anteneh Tesfaye, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Al Hallak, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Anthony F. Shields, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

